People
Origin, a 3D printing specialist for medical devices, just completed clinical trials and validation of its 3D-printed nasopharyngeal swabs for use in COVID-19 test kits. It is scaling up production and accepting orders to manufacture millions of the swabs.
The investigators assayed the levels and analyzed the expression patterns of more than 3,000 proteins in brain and cerebrospinal fluid samples collected at centers across the U.S.
Although the COVID-19 death toll has not yet reached the numbers of H3N2, it still continues to climb.
In its daily blog about the precautions the company is taking to ensure continued service to the world, Amazon said it will build its own testing facilities for employees.
On Thursday, the American Medical Association doubled down on its stance against using off-label medicines like hydroxychloroquine and chloroquine to treat COVID-19 patients.
As COVID-19 has swept across the world, companies have had to make significant adjustments to the way business is conducted in a global economy. It has impacted all types of operations, including clinical trials.
Biopharma companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
If you’re having trouble keeping up with multiple industry programs aimed at COVID-19, you’re not alone. But, there is a new solution that can help you see the proverbial forest from the trees – Signals Analytics COVID-19 Playbook.
Biopharma companies are attacking the COVID-19 pandemic from many fronts. Emergent BioSolutions is among those leading the fight.
The world continues to wait with bated breath for a treatment for COVID-19, and Pluristem Therapeutics appears to be on the cusp of providing some hope.
PRESS RELEASES